Previous 10 | Next 10 |
2023-05-09 10:00:33 ET Gainers: TScan Therapeutics ( TCRX ) +151% . Ensysce Biosciences ( ENSC ) +60% . Novavax ( NVAX ) +36% . Y-mAbs Therapeutics ( YMAB ) +30% . Longeveron ( LGVN ) +26% . Losers: Enanta Pharmaceuti...
AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE PR Newswire Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Re...
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million ...
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of...
2023-05-02 10:02:29 ET Gainers: TScan Therapeutics ( TCRX ) +17% . Vivani Medical ( VANI ) +15% . SI-BONE ( SIBN ) +13% . Kiniksa Pharmaceuticals ( KNSA ) +12% . Harmony Biosciences ( HRMY ) +8% . Losers: Community Health ...
Deepens the Board’s clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors advance Company also announces key leadership promotions WALTHAM, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX...
2023-03-31 08:16:30 ET TScan Therapeutics ( NASDAQ: TCRX ) has announced that its Board of Directors has appointed Gavin MacBeath, Ph.D., as acting CEO, effective March 28, 2023. He will continue to serve as Chief Scientific and Operating Officer. David Southwell has s...
David Southwell steps down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to serve as acting CEO Company reaffirms previously disclosed milestones and cash runway; provides clinical program update WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- TScan Therapeuti...
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the first ...
WALTHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Compan...
News, Short Squeeze, Breakout and More Instantly...
TScan Therapeutics Inc. Company Name:
TCRX Stock Symbol:
NYSE Market:
TScan Therapeutics Inc. Website:
2024-07-26 15:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-16 12:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...